07 Jan 2001

Blastoestimulina 2% - España

Updated: 07 Jan 2001

Blastoestimulina 2% polvo 5 g

Cicatrización de: heridas, quemaduras, úlceras tórpidas, úlceras de córnea, lesiones ulcerosas de la lepra etc.

Blastoestimulina 2% Description, Presentation and Dosage

Blastoestimulina 2% Description

Blastoestimulina 2% Drug Class Description


Blastoestimulina 2% Drug Description


Blastoestimulina 2% Presentation

Blastoestimulina 2% Presentation

Ampollas: dosis de ataque: 25 mg. (2,5 ml) vía i.m. o s.c. profunda al día ó 3 veces por semana; dosis de mantenimiento: 25 mg (2,5 ml) por vía i.m. cada 3 ó 4 días. Polvo: 1 a 3 aplicaciones al día. Aerosol: Pulverizar una ligera capa de producto sobre la herida, 1-3 veces al día.

Blastoestimulina 2% Manufacturer


Related Learning Zones

Heart Failure

Heart Failure is a progressive chronic disorder that results in the inability of the heart to pump blood efficiently to the bodys tissues.

Chronic heart failure is an increasing public health problem; the growing prevalence in industrialised countries means that 1-2% of the adult population of these countries are now thought to have chronic heart failure.1-3 Estimates suggest that the prevalence in Europe, USA and Japan could increase by approximately 16.5% over the next ten years.4

Symptomatic Asthma

Symptomatic Asthma

Focusing on the lack of symptomatic control in patients with asthma, the new Symptomatic Asthma Learning Zone, consisting of a Disease Awareness section and an RCGP-accredited CME, is free to access for all epgonline.org members, and has been designed to provide them with the information they need to effectively manage the symptoms of their patients with asthma.

Blastoestimulina 2% Dosage

Blastoestimulina 2% Precautions, Reactions and Contraindications

Blastoestimulina 2% Special Precautions

Blastoestimulina 2% Adverse Reactions

Blastoestimulina 2% Adverse Reactions

Descamación de la piel.

Related Drugs - Dermatología

Back to top